rdf:type |
|
lifeskim:mentions |
umls-concept:C0002199,
umls-concept:C0016072,
umls-concept:C0026948,
umls-concept:C0027651,
umls-concept:C0034790,
umls-concept:C0035820,
umls-concept:C0040649,
umls-concept:C0087111,
umls-concept:C0521447,
umls-concept:C0683598,
umls-concept:C1704259,
umls-concept:C1705987
|
pubmed:issue |
1
|
pubmed:dateCreated |
2009-1-9
|
pubmed:abstractText |
Interferon (IFN)-alpha is widely used in the treatment of mycosis fungoides (MF) and when used in combination with photochemotherapy (psoralen plus ultraviolet A, PUVA) both improved response and duration of complete remission have been reported. However, in spite of encouraging results of the initial studies, currently there is no information available on specific prognostic factors enabling prediction of patients' resistance to PUVA +/- IFN-alpha treatment.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1365-2133
|
pubmed:author |
pubmed-author:AlvarezMM,
pubmed-author:Fernández HerreraJJ,
pubmed-author:FragaJJ,
pubmed-author:MontesSS,
pubmed-author:Ortiz-RomeroP LPL,
pubmed-author:PirisM AMA,
pubmed-author:Rodriguez-PeraltoJ LJL,
pubmed-author:TraceyLL,
pubmed-author:VidalSS,
pubmed-author:Villuendas DeceasedRR,
pubmed-author:WozniakM BMB
|
pubmed:issnType |
Electronic
|
pubmed:volume |
160
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
92-102
|
pubmed:meshHeading |
pubmed-meshheading:18945306-Adolescent,
pubmed-meshheading:18945306-Adult,
pubmed-meshheading:18945306-Aged,
pubmed-meshheading:18945306-Combined Modality Therapy,
pubmed-meshheading:18945306-Drug Resistance, Neoplasm,
pubmed-meshheading:18945306-Female,
pubmed-meshheading:18945306-Gene Expression Profiling,
pubmed-meshheading:18945306-Humans,
pubmed-meshheading:18945306-Immunohistochemistry,
pubmed-meshheading:18945306-Interferon-alpha,
pubmed-meshheading:18945306-Male,
pubmed-meshheading:18945306-Middle Aged,
pubmed-meshheading:18945306-Mycosis Fungoides,
pubmed-meshheading:18945306-NF-kappa B,
pubmed-meshheading:18945306-PUVA Therapy,
pubmed-meshheading:18945306-Receptors, Antigen, T-Cell,
pubmed-meshheading:18945306-Signal Transduction,
pubmed-meshheading:18945306-Skin Neoplasms,
pubmed-meshheading:18945306-Treatment Outcome,
pubmed-meshheading:18945306-Young Adult
|
pubmed:year |
2009
|
pubmed:articleTitle |
Psoralen plus ultraviolet A +/- interferon-alpha treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor-kappaB and T-cell receptor pathways.
|
pubmed:affiliation |
Molecular Pathology Program, Centro Nacional de Investigaciones Oncológicas, Madrid, Spain.
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|